Scholarlink

Background <p>Hashimoto’s encephalopathy (HE) is a rare, underdiagnosed, steroid-responsive autoimmune condition associated with thyroid autoimmunity.</p> Case presentation <p>An 83-year-old female patient was admitted to hospital displaying symptoms of subacute cognitive decline, dysarthria and myoclonus. She had a history of Hashimoto’s thyroiditis and diabetes. Given the patient’s age and comorbid diabetes, the potential risks associated with steroid treatment were considered excessive. She was given an 800&#xa0;mg dose of efgartigimod-α, which swiftly improved her ambulatory stability and cognitive function. Approximately four weeks later, the patient exhibited a clinical relapse and underwent a subsequent treatment cycle with efgartigimod-α. Each treatment cycle significantly alleviated the patient’s symptoms.</p> Conclusions <p>The report under consideration herein highlights the clinical presentation, diagnostic challenges, and therapeutic considerations of HE, emphasizing the potential role of Neonatal Fc receptor (FcRn) antagonists, such as efgartigimod-α, as an emerging treatment strategy. The repeated administration of FcRn antagonists has been posited as a potential therapeutic intervention for patients diagnosed with hormone-intolerant Hashimoto’s encephalopathy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Recurrent steroid-intolerant Hashimoto’s encephalopathy responsive to single-dose neonatal Fc receptor antagonist: a case report and literature review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月23日

查看全文
  • Xiangliang Wang,
  • Gang Wang,
  • Jinjin Xu,
  • Yongjie Bai,
  • Wenjun Yan,
  • Xinsheng Liu,
  • Shukui Zhang,
  • Ruile Shen

摘要

Background

Hashimoto’s encephalopathy (HE) is a rare, underdiagnosed, steroid-responsive autoimmune condition associated with thyroid autoimmunity.

Case presentation

An 83-year-old female patient was admitted to hospital displaying symptoms of subacute cognitive decline, dysarthria and myoclonus. She had a history of Hashimoto’s thyroiditis and diabetes. Given the patient’s age and comorbid diabetes, the potential risks associated with steroid treatment were considered excessive. She was given an 800 mg dose of efgartigimod-α, which swiftly improved her ambulatory stability and cognitive function. Approximately four weeks later, the patient exhibited a clinical relapse and underwent a subsequent treatment cycle with efgartigimod-α. Each treatment cycle significantly alleviated the patient’s symptoms.

Conclusions

The report under consideration herein highlights the clinical presentation, diagnostic challenges, and therapeutic considerations of HE, emphasizing the potential role of Neonatal Fc receptor (FcRn) antagonists, such as efgartigimod-α, as an emerging treatment strategy. The repeated administration of FcRn antagonists has been posited as a potential therapeutic intervention for patients diagnosed with hormone-intolerant Hashimoto’s encephalopathy.